

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

(Stock code: 6488)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board

SBI Holdings, Inc.

Yoshitaka Kitao

Representative Director,

President & Chief Executive Officer

Japan, 8 November 2012

As of the date of this announcement, the executive Directors are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa, Mr Tomoya Asakura, Mr Shumpei Morita, Mr Noriaki Maruyama and Mr Peilung Li, the non-executive Directors are Mr Yasutaro Sawada, Mr Hiroyoshi Kido, Mr Noriyoshi Kimura, Mr Hiroshi Tasaka and Mr Takashi Okita and the independent non-executive Directors are Mr Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr Akihiro Tamaki and Mr Masanao Marumono.



November 8, 2012
SBI Holdings, Inc.
(TOKYO: 8473 / Hong Kong: 6488)

**Notice on Acquisition of Equity Interest in German Biotech Firm Engaged in 5-ALA
Related Drug Business in Europe**

SBI Holdings, Inc. (“SBIH”) hereby announces that it has agreed with medac GmbH (Head office: Hamburg, Germany; “medac”), a German pharmaceutical company, to acquire 20% of its equity in photonamic GmbH & Co. KG (Head office: Wedel, Germany: “photonamic”). photonamic is medac’s subsidiary and it develops drugs using 5-aminolevulinic acid (5-ALA). SBIH will carry out this acquisition through its office in Europe, and it has concluded a related contract with medac.

photonamic is engaged in research and development of drugs that use 5-ALA under the umbrella of medac, a partner of SBIH in 5-ALA related businesses that manufactures and sells a 5-ALA-based interoperative diagnostic drug for brain tumors in Europe. The interoperative diagnostic drug for brain tumors was approved by the European Medicines Agency (EMA) in 2007, and is now sold in over 20 countries in Europe, including Germany and the U.K. The above equity acquisition is to make photonamic a joint venture between SBIH and medac. Capitalizing on this, photonamic is expected to cooperate with SBI Pharmaceuticals Co., Ltd., a drug company engaged in 5-ALA businesses under the umbrella of the SBI Group, and jointly promote the development of medicine so as to broaden the adaptation of interoperative diagnostic drugs in Europe.

SBIH, regarding the Biotechnology-related Business as the largest growth field of the SBI Group, is accelerating operations of the 5-ALA business in Japan and abroad. Taking advantage of this investment in photonamic, SBIH will further accelerate operations of the 5-ALA business in Europe, while continuously establishing a global business structure. SBIH is also considering gradually increasing its ownership percentage in photonamic in the future.

Outline of photonamic GmbH & Co. KG

Corporate name:	photonamic GmbH & Co. KG
Head office:	Wedel, Germany
Business:	Research, development, and other handling of pharmaceuticals related to 5-ALA
Capital:	51,129,000 euros
Establishment:	March 2002

For further information, please contact:

SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126